2cureX has received a grant from the Innovation Fund Denmark to support clinical development of a novel IndiTreat® product.
2cureX announced today that it has been awarded a grant of 1.5 M DKK to support the development of IndiTreat® Neo, a test to support therapy decision-making in neo-adjuvant treatment of non-metastatic colorectal cancer.
Acceleration of IndiTreat® portfolio expansion to early stages of colorectal cancer
In the last years, 2cureX has successfully introduced three CE-IVD marked IndiTreat® tests for metastatic colorectal cancer (mCRC) into the European market. This new grant will support the expansion to earlier, non-metastatic stages of colorectal cancer (CRC).
Almost all patients in stages II and III undergo surgery of their colorectal tumor. Chemotherapy treatment prior to surgery (neoadjuvant) led to significant tumor reduction and prolonged disease-free-survival in a large, international randomized trial (FOXTROT) including more than 1500 patients and is on the way to becoming standard-of-care. With the support from the Innovation Fund Denmark, IndiTreat® will be used for selecting the most efficacious neoadjuvant chemotherapy treatment in a new series of trials. Success in these neoadjuvant trials will pave the way for introduction of a new IndiTreat® Neo product and change of international guidelines for treatment of CRC.
Ole Thastrup, CSO and Founder of 2cureX says “Clinical validation of an IndiTreat® Neo test will provide the basis for an exciting expansion of the IndiTreat® product portfolio to include tests for both metastatic and non-metastatic disease stages. This will not only dramatically increase the number of eligible patients, but also show the broad applicability of the IndiTreat® technology”, Ole Thastrup continues: “A clear medical need for an IndiTreat® Neo test has been confirmed by a large number of hospitals covered through our distribution network”.
